Local surface plasmon resonance detector
By using color change reaction between gold nanoparticles and polyclonal antibody compositions, the problems of low efficiency and high cost of existing diagnostic tools are solved, and the rapid and sensitive detection of biomarkers is achieved, which is suitable for a variety of medical applications.
Patent Information
- Application Number
- CN202380031944.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-16
- Filing Date
- 2023-03-23
- Publication Date
- 2024-11-26
AI Technical Summary
Existing diagnostic tools are inefficient, costly and long reaction times, making it difficult to detect biomarkers quickly and accurately, especially in the early stages of infectious and non-infectious diseases.
Using gold nanoparticles and polyclonal antibody compositions, the target biomarkers are detected through color change reactions, and the migration and absorption of visible color changes from red to blue or purple are achieved by using the migration of plasmon band energy. .
High sensitivity detection of ultra-low concentration biomarkers is achieved, simplifies equipment and operations, reduces costs, is suitable for all sizes and environments from laboratory to on-site care, suitable for portable and wearable medical devices.
Smart Images

Figure CN119032272A_ABST
Abstract
Description
[0001] The present invention relates to compositions for detecting targets such as biomarkers, detectors for detecting targets such as biomarkers, and related methods.
[0002] The risk of a global pandemic caused by an infectious agent has been high over the past decade. The COVID-19 pandemic and its waves of infection have demonstrated the need for practical diagnostic tools. The low efficiency, high cost and long test response times of existing diagnostic tests indicate the need to change the diagnostic armamentarium from expensive and slow laboratory-based technologies to easy-to-use, reliable and rapid diagnostic tools.
[0003] International health agencies are working vigorously to control this pandemic by exploring all aspects of therapeutic development, with a focus on developing innovative diagnostic tools for rapid and selective detection of COVID-19 infection. While the COVID-19 pandemic has revealed the need for better diagnostics for infectious diseases, non-infectious diseases such as cancer and dementia also require early diagnostic tools (and preferably tools that work in the pre-symptomatic or asymptomatic period), which will improve clinical decision-making and medical treatment.
[0004] Better diagnostic tools are essential to delivering precision medicine, a model of healthcare that proposes customized health care in which medical decisions, treatments, practices or products are tailored to patient subpopulations, rather than a one-drug-fits-all model. In precision medicine, diagnostic tests can be used to select appropriate and optimal therapies based on a patient’s genetic makeup or other molecular or cellular analysis.
[0005] One of the objects of the present invention is to provide products and methods for detecting targets such as biomarkers quickly or cheaply or non-invasively or with high sensitivity or high specificity, and preferably with all of these features. Another object of the present invention is to provide products and methods for improved timely point-of-care diagnostic testing for infectious diseases, non-infectious diseases or more general biomarkers.
[0006] One of the objects of the present invention is also to provide products and methods for detecting targets such as biomarkers, the development process of which from laboratory scale to pilot plant scale or commercial scale is simple and / or low-cost.
[0007] It is also an object of the present invention to provide products and methods for detecting targets such as biomarkers, which do not require highly sophisticated laboratories or expert personnel and / or are low-cost and / or easy to use.
[0008] It is also an object of the present invention to provide products and methods for detecting targets such as biomarkers which overcome current limitations such as lack of accuracy, lack of compatibility with different biological fluids, low temperature stability or lack of portability.
[0009] It is also an object of the present invention to provide products and methods for detecting targets such as biomarkers that improve upon current diagnostic capabilities with respect to specificity, speed or cost while enhancing sensitivity and / or reducing instrument size.
[0010] One of the objects of the present invention is also to provide products and methods for detecting targets such as biomarkers, which can reduce the size of the sensor. This is very useful for providing portable, wearable or implantable medical devices. It is also useful for the integration of biosensors with other medical instruments.
[0011] One of the objects of the present invention is also to provide products and methods for detecting low concentrations of targets such as biomarkers and thus having the potential to detect early stages of a disease. Early detection of biomarkers is particularly necessary for long-term diseases such as cardiovascular disease, cancer, chronic respiratory disease and diabetes.
[0012] The invention disclosed herein may improve the ability to detect infectious agents in major reservoirs (such as animals and wastewater) and improve global response planning for existing or potential health risk events.
[0013] In a first aspect, the present invention provides a composition according to claim 1.
[0014] When gold nanoparticles and polyclonal antibodies are dispersed in a liquid, the composition according to the present invention scatters light differently than when they are self-assembled in a liquid. Plasmons appear on the surface of gold nanoparticles. Plasmons are coherent delocalized electron oscillations. Plasmon bands are energy levels associated with plasmons. The transition from dispersed gold nanoparticles to self-assembled gold nanoparticles results in the migration of plasmon band energy. The absorption of these different energy bands provides visible color transitions from red to blue and from blue to red.
[0015] Compositions according to the present invention can be dispersed in liquids in which they have a red color. When the surface of the nanoparticles is in contact, short-range interactions allow bonding and other interactions of the nanoparticles to the nanoparticles. Along with the formation of these bonds or interactions, the color of the solution changes from red to blue, and sometimes to purple. These color changes are color changes generated by plasmons.
[0016] The composition according to the present invention can use the reaction between the polyclonal antibody (attached to the gold nanoparticle) and the target in the sample (which binds to the polyclonal antibody) as a physical process to contact or interact with the nanoparticle surface. This causes a color change from red to blue, which indicates the presence of the target (e.g., biomarker) in the sample. Figure 1 A schematic diagram of how a composition according to the invention self-assembles in the presence of a biomarker is shown. Gold nanoparticles 1 are linked, preferably covalently, to polyclonal antibodies 2. Biomarkers 3 from the added sample have several different regions 4 that can bind to the antibody 2. The binding of the polyclonal antibodies to different regions of the biomarker brings the nanoparticles closer together (as shown on the right side of the reaction), thereby providing a color change from red (left side of the reaction) to blue (right side of the reaction).
[0017] Figure 2 Schematic diagram showing how polyclonal antibodies bind to biomarkers compared to monoclonal antibodies. Monoclonal antibodies 5 bind to only one region 6 of the biomarker. This prevents them from providing the self-assembly effect provided by the binding of different parts 7 and 7' of the polyclonal antibodies to corresponding (different) parts 8 and 8' of the biomarker.
[0018] Figures 4A-4D Figure 2 shows the binding of nanoparticles and monoclonal antibody complexes to biomarkers compared to the binding of nanoparticles and polyclonal antibody complexes to biomarkers. Monoclonal antibodies do not produce self-assembly of nanoparticles ( Figure 4A ), while polyclonal antibodies do produce self-assembly of nanoparticles and subsequent color change from red to blue or purple. Color change e.g. Figure 4C The biomarker concentration provides a color change from red to blue. Figure 4D The degree of color change is shown to provide an indication of the stage of infection in the patient. As the biomarker concentration increases with infection, the color change becomes darker until it reaches gray. In the case of very high biomarker concentrations, the effect may be eliminated due to rapid and strong reactions, resulting in precipitation of components.
[0019] The use of polyclonal antibodies connected to gold nanoparticles can surprisingly greatly improve the ability to detect ultra-low concentrations of targets bound to the polyclonal antibodies. Therefore, the present invention can be used to detect ultra-low concentrations of targets such as specific biomarkers. It is believed that the ability of polyclonal antibodies to self-assemble gold nanoparticles very effectively in response to target molecules bound to the polyclonal antibodies is due to the complex structure of the polyclonal antibodies.
[0020] Polyclonal antibodies (pAbs) are secreted by different B-cell lineages in the body (whereas monoclonal antibodies come from a single cell lineage). Polyclonal antibodies are immunoglobulin molecules that react against a specific target (which can be a biomarker), with each clone recognizing a different region (epitope) of the target. Thus, a specific target will be detected by more than one antibody. Multiple interactions occur between the target and the polyclonal antibodies. This in turn attracts the gold nanoparticles (to which they are attached) into a compact, self-assembled structure, triggering a change in the energy of the plasmon band and a resulting visible color change.
[0021] Unexpectedly, the present invention can provide such technical effects without the natural aggregation of the "nanoparticle and linked polyclonal antibody" complex, which would otherwise hinder the color transition. Natural aggregation in solution can induce color change in the absence of any target (such as a biomarker), thereby hindering the sensitivity of the color transition to the target.
[0022] The prefix "nano" refers to a material having at least one dimension of its structure that is less than 100 nanometers (nm).
[0023] The compositions and related methods according to the present invention can be easily manufactured / implemented. The use of gold nanoparticles provides an acceptable and recognizable visual color change. Gold nanoparticles are also non-toxic.
[0024] A biomarker is a measurable indicator of a biological state. By definition, a biomarker is "an objectively measured and evaluated characteristic that serves as an indicator of a normal biological process, a pathogenic process, or a pharmacological response to a therapeutic intervention". In general, biomarkers can be physical biomarkers (e.g., proteins) and non-physical biomarkers (e.g., heart rate). The biomarkers referred to herein are physical biomarkers, such as those that can physically interact with polyclonal antibodies.
[0025] Furthermore, the scale-up process from laboratory scale to pilot plant scale or commercial scale is very simple and cost-effective.
[0026] Preferably, each polyclonal antibody is linked to the gold nanoparticle via a covalent bond.
[0027] Preferably, each polyclonal antibody is linked to the gold nanoparticles via a linker. The linker may include a group derived from N-hydroxysulfosuccinimide. This provides a secure attachment of the polyclonal antibodies to the nanoparticles.
[0028] The linker may comprise an ester bond. This provides a secure attachment of the polyclonal antibody to the nanoparticle, which is easy to produce.
[0029] The polyclonal antibodies can be attached to the gold nanoparticles individually via the primary amide groups. This provides a strong attachment of the polyclonal antibodies to the nanoparticles, which is easy to produce.
[0030] The polyclonal antibody may be adapted to specifically bind to one of a peptide, a protein, a hormone, an antibody, and an organic compound. The entity to which the polyclonal antibody is adapted to bind is described herein as a target.
[0031] Preferred targets and 'target and polyclonal antibody' combinations exemplified herein are as follows:
[0032] 1. Peptide (DDDDK peptide) / polyclonal anti-DDDDK tag (with Tag sequence binding) antibody (ab1162).
[0033] 2. Recombinant human topoisomerase IIα protein (ab159735) / polyclonal anti-topoisomerase IIα antibody (ab12318).
[0034] 3. Recombinant anti-human topoisomerase IIα antibody from rabbit (ab52934).
[0035] 4. Polyclonal goat anti-rabbit IgG H&L (ab182016).
[0036] 5. Avian CORT / anti-corticosterone antibody produced in rabbit / anti-corticosterone antibody for use in birds (Sigma C8784-100TST).
[0037] 6. Human CORT corticosterone CORT 500 mg (Sigma 27840).
[0038] 7. Extraction and detection of non-commercial avian stress hormone CORT in methanol.
[0039] 8. Anti-human IgG antibody (ab2410).
[0040] 9. Anti-human IgM antibody (ab26867).
[0041] 10. Anti-human IgA antibody (ab2411).
[0042] In a preferred embodiment, the polyclonal antibodies may be suitable for binding to one or more of the following: amyloid beta peptide, CSF biomarkers, natriuretic peptides, IgG, IgM, IgA, CigG, ANA, anti-dsDNA (anti-double-stranded DNA antibodies), VOCs (volatile organic compounds, such as hormones), CEA, troponin T / C / I, CRP / CD27 / CD38, CA / GP120 / GP41, cortisol, epinephrine and norepinephrine. These biomarkers serve as indicators of diseases selected from cancer, dementia, CVD, tuberculosis, malaria and HIV. Biomarkers for sepsis, cholera and pneumonia can also be detected by selecting appropriate polyclonal antibodies. Preferably, the polyclonal antibodies are suitable for binding to specific biomarkers associated with any medical condition described herein, including the following as shown in Table 1:
[0043]
[0044] Table 1
[0045] Table 1 shows examples of target categories detectable using the products and methods according to the invention. The examples in the detailed description below show data indicating that the invention can detect specific hormones, peptides, antibodies (both specific and non-specific) and proteins. Other targets belonging to these category headings, including specific biomarkers and other targets listed herein, are also considered detectable by the invention due to their similar properties or structures and the general mechanism of action of polyclonal antibody binding.
[0046] Preferably, the polyclonal antibodies are suitable for binding to a virus such as influenza A, influenza B or HIV-1 CA protein, HIV-1 envelope glycoprotein GP120 HIV-1 GP120, GP 41 or a component thereof such as the spike protein or nucleoprotein.
[0047] Preferably, the polyclonal antibody is suitable for binding to an antigen or capsid protein, such as an antigen or capsid protein of a virus such as a respiratory virus infection (RVS). For example, IgG human anti-SARS-CoV-2 and any variant thereof can be linked to nanoparticles. For example, anti-SARS-CoV-2 (COVID-19) spike antibodies generated against the recombinant SARS-CoV-2 (2019-nCoV) spike protein (S2) domain or anti-SARS-CoV-2 (COVID-19) nucleocapsid antibodies generated against the recombinant SARS-CoV-2 (2019-nCoV) nucleocapsid protein can be linked to nanoparticles.
[0048] Preferably, the polyclonal antibodies are suitable for binding to biomarkers associated with Helicobacter pylori, poxvirus, tuberculosis (TB), pneumonia or Vibrio cholerae.
[0049] The gold nanoparticles may have a polyethylene glycol (PEG) surface layer. This layer may be a complete or partial coating. This layer is preferably applied before the gold nanoparticles are connected to the polyclonal antibodies. This increases the extent to which the polyclonal antibodies can be connected to the nanoparticles. A composition is provided that is easier to manufacture and more sensitive to target molecules due to the greater number of polyclonal antibodies connected to the gold nanoparticles. The PEG molecules also provide a more stable nanoparticle and polyclonal antibody complex that is less likely to self-aggregate prematurely, or to self-aggregate prematurely in the absence of a specific target.
[0050] Preferably, the PEG molecule includes a carboxylic acid group, which is preferably located at or near the end of the PEG molecule. This enhances the above effect by providing a PEG molecule that is more easily attached to the polyclonal antibody and forms a stronger bond, especially when using NHS / EDC linking reactions.
[0051] Preferably, the polyethylene glycol chain length is 1000-3000, more preferably 1000-2500. These ranges enhance the above effects.
[0052] Preferably, the gold nanoparticles are substantially spherical. The gold nanoparticles may be spherical.
[0053] The diameter of the gold nanoparticles can be greater than 3.5 nm. This provides an acceptable level of surface plasmons for the composition, and therefore provides an acceptable level of visible color. The diameter of the gold nanoparticles can be 5-50 nm, and preferably 10-40 nm. These ranges provide acceptable surface plasmon levels for the composition, and therefore provide a strong visible color, so that the color change is easy to identify.
[0054] The composition can be a powder. The composition can be lyophilized. This provides a convenient form for transporting the composition, which can be added to a liquid sample or a different liquid with a sample added. The lyophilized or powdered form of the composition can also be used to add to a detection device that is delivered to the user in a dry form. The powder or lyophilized form can be adhered to the surface of the detection device. The user then adds a sample or a separate liquid to perform a detection test.
[0055] In another aspect, the invention provides a liquid comprising a composition as described herein, wherein the composition (which comprises gold nanoparticles and polyclonal antibodies) is dispersed in the liquid. This provides a convenient medium into which a sample can be introduced to detect a target in the sample.
[0056] The concentration of the composition including the gold nanoparticles and the polyclonal antibody in the liquid may be such that the absorbance of the liquid is 0.1-1 AU (absorbance unit).
[0057] The liquid may include a liquid selected from the group consisting of water, methanol, plasma, saliva, serum, a sodium chloride solution having a concentration of 50 mM to 200 mM, a potassium chloride solution having a concentration of 50 mM to 200 mM, a magnesium chloride solution (MgCl2) having a concentration of 5 mM to 100 mM, a PBS (phosphate buffered saline) having a concentration of less than 10% (preferably about 0.1%), and a SBB (sodium borate buffer) having a concentration of less than 1 M (preferably about 0.1 M). These liquids provide an acceptable low level of natural aggregation of gold nanoparticles in the composition.
[0058] Ethanol is less preferred for use in the present invention as it can lead to aggregation of dispersed gold nanoparticle / polyclonal antibody complexes in the absence of any target (to which the polyclonal antibody binds). In a preferred embodiment, the solution is substantially free of ethanol.
[0059] In a further aspect, the present invention provides a method of preparing the composition described herein, comprising the step of linking the gold nanoparticles to the polyclonal antibodies.
[0060] The method may also include the step of attaching a linker to the gold nanoparticles before linking the gold nanoparticles to the polyclonal antibodies. The linker may be an activated group that increases the ability of the gold nanoparticles to link to the polyclonal antibodies.
[0061] The step of attaching a linker to the gold nanoparticles may include the steps of reacting the gold nanoparticles with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride followed by N-hydroxysulfosuccinimide. This is called an EDC, NHS reaction.
[0062] The step of connecting the gold nanoparticles and the polyclonal antibodies can be carried out in the presence of polyethylene glycol (PEG). Similarly, PEG can be applied to the nanoparticles before any polyclonal antibodies are connected to the nanoparticles. Preferably, the nanoparticles include part or all of a coating on its surface, and this coating includes a citrate group or other carboxylic acid derivative groups. These groups have established an activated part or all of a coating, which is very suitable for further ligation reactions. Preferably, the uncoated gold nanoparticles are formed by treating with sodium citrate or another carboxylate solution. Preferably, the nanoparticles including the activated part or all of a coating are mixed with a liquid including PEG so that the activated part or all of a coating is provided with a part or all of a coating.
[0063] Partial or complete coating of PEG increases the degree of attachment of polyclonal antibodies to nanoparticles. Therefore, the number of polyclonal antibodies that can be attached to the nanoparticles treated with PEG is greater than the number of polyclonal antibodies that can be attached to the corresponding untreated nanoparticles. One mechanism by which PEG treatment achieves this result is the increase in surface area provided by the PEG layer. The increased polyclonal antibody uptake by the nanoparticles treated with PEG provides a composition that is easier to manufacture and more sensitive to target molecules due to the greater number of polyclonal antibodies attached to the gold nanoparticles. Partial or complete coating of PEG on the nanoparticles is also believed to prevent unwanted natural aggregation (which may induce unwanted color changes).
[0064] Preferably, the polyethylene glycol chain length is 1000-3000, and preferably 1000-2500. This enhances the above effects and ensures that the PEG treatment does not affect the plasmonic characteristics of the nanoparticles. The presence of a partial or full coating of PEG improves the detection of small targets such as hormones and small (e.g. molecular) biomarkers.
[0065] Preferably, before the gold nanoparticles are linked to the polyclonal antibodies (or linkers), the gold nanoparticles are treated so that they have citrate groups disposed on their surface, preferably in the form of a layer (as described above). This provides a functionalized surface to which linkers such as EDC-NHS reaction products or polyclonal antibodies can be easily and securely attached.
[0066] In some embodiments, fluorescently labeled polyclonal antibodies can be used to show that binding has occurred between gold nanoparticles and polyclonal antibodies. The fluorescence of the linked gold nanoparticle and polyclonal antibody complex can be detected using a fluorescence microscope.
[0067] In a further aspect, the present invention provides a method for detecting a target in a sample, comprising the step of combining a composition as described herein or a liquid as described herein with the sample. The sample may be a liquid.
[0068] The sample may have a volume of 3-5 microliters. This is preferred because only a very small amount of the composition containing nanoparticles and polyclonal antibodies is required. However, this small volume is still sufficient to give a recognizable result signal.
[0069] The liquid or sample may include a buffer having a pH range of 4-9, and preferably 4-8.5, 4-8, or 4-7. This prevents unwanted or premature aggregation of the nanoparticle and polyclonal antibody composition. pH beyond these ranges is less preferred because it may drive aggregation by changing the surface charge of the nanoparticle.
[0070] The concentration of the target in the sample can be 5x 10 -18 molar to 1x 10 -9 This provides a method for ultra-low concentration detection.
[0071] The sample can be a saliva sample, a urine sample, a soft tissue sample, a serum sample, a plasma sample or an aqueous sample. This provides a wide range of flexibility for the sample being tested. In a preferred embodiment, the liquid and the sample will be of the same type. This helps to prevent unnecessary or premature self-assembly. For example, if the sample to be run is a plasma sample, the liquid (containing the nanoparticles and polyclonal antibody complexes combined with the sample) can include plasma.
[0072] The method may include a diagnostic step, wherein the color change indicates the presence of a target that is a biomarker for a disease, thereby diagnosing the disease.
[0073] The combination of the composition or liquid and the sample can undergo a color change from red to blue. This occurs when the sample contains a target bound by the polyclonal antibody in the composition or liquid.
[0074] Preferably, when the sample comprises a target to which the polyclonal antibody binds, the solution undergoes a color change in less than 3 minutes, and preferably less than 2 minutes, and preferably less than 1 minute after the sample and the solution are combined.
[0075] The target can be a biomarker, and wherein, when the composition described herein or the liquid described herein is combined with a sample, there are gold nanoparticles each attached to a probe that binds to the biomarker. The advantages of this method are Fig. 9C and Fig.11 and discussed and exemplified in the corresponding detailed description below. The method can be used to detect specific types of antibodies that serve as biomarkers for specific conditions.
[0076] The target can be an antibody that binds to the probe. The target can be a specific antibody that specifically binds to the probe. For example, the method can detect a specific type of IgG or IgM or IgA antibody.
[0077] The probe can be a protein such as a disease antigen or a portion thereof, an enzyme or a peptide. The probe can be a spike protein or a nucleocapsid protein associated with any of the disorders described herein.
[0078] In a further aspect, the invention provides a detection test comprising a first liquid or a first composition as described herein.The test may be a device.
[0079] Detection tests may be suitable for carrying out the methods described herein.
[0080] The detection test may be adapted to transmit the test results to a remote location. It may do so via a wireless network and / or via the Internet. The detection test may be coupled to a mobile device such as a phone or tablet or computer to display the test results or transmit the test results to a remote location.
[0081] The detection test may include a second composition as described herein or a second liquid as described herein, wherein a first composition as described herein or a first liquid as described herein, and
[0082] A second composition as described herein or a second liquid as described herein
[0083] Different polyclonal antibodies are included so that the first composition or first liquid and the second composition or second liquid described herein are suitable for detecting different targets. That is, the test can include two different liquids, a combination of two different compositions, or any combination of liquids and compositions, provided that the polyclonal antibodies that bind to each liquid / composition are different from the polyclonal antibodies that bind to the other liquid / composition.
[0084] Different targets may all be biomarkers associated with a particular disease. For example, one biomarker may be the presence of a specific IgM antibody, and another biomarker (to which the relevant polyclonal antibody binds) may be a specific IgG antibody. These embodiments may provide a patient with a rapid and accurate method for assessing the stage of infection by the presence or absence of IgM and IgG antibodies. A hypothetical example of such a detector and method is provided in Example 8 discussed below.
[0085] The first composition or first liquid and the second composition or second liquid can be spaced apart so that they can react with different samples independently. This can allow a user to run, for example, a blood sample and a urine sample in the same detection test.
[0086] The first composition or first liquid and the second composition or second liquid may be suitable for reacting with a single sample or with different samples simultaneously. This provides a rapid test that is still able to detect multiple targets.
[0087] Embodiments of the present invention will now be described with reference to the accompanying drawings and the following examples, in which:
[0088] Figure 1 A schematic diagram showing how a composition according to the present invention self-assembles in the presence of a biomarker.
[0089] Figure 2 Schematic diagram showing how polyclonal antibodies bind to biomarkers compared to monoclonal antibodies.
[0090] Figure 3 Reaction steps that can be used to link polyclonal antibodies to gold nanoparticles are shown.
[0091] Figures 4A-4D Binding of a nanoparticle and monoclonal antibody complex to a biomarker is shown compared to binding of a nanoparticle and polyclonal antibody complex to a biomarker, and subsequent self-assembly and color change.
[0092] Figure 5 A-5F shows the reaction steps that can be used to link fluorescent polyclonal antibodies to gold nanoparticles and the fluorescence microscopy image obtained in Example 1.
[0093] Figure 6 A-6D shows the detection results of protein / enzyme biomarkers as described in Example 2.
[0094] Figure 7 A-7C shows the results of detection of peptide biomarkers as described in Example 3.
[0095] Figure 8 A-8D shows the results of the cortisone test described in Example 4.
[0096] Figures 9A-9D Results for detection of general and specific types of antibodies are shown.
[0097] Fig.10 The reactions occurring in the viral antigen sensor described in Example 6 are shown.
[0098] Fig.11 The reactions occurring in the viral serological sensor described in Example 7 are shown.
[0099] Fig.12A typical graph of antibody production versus days post infection is shown. The array also shows exemplary results when using a multi-biomarker sensor according to the present invention to identify different targets, as described in Example 8.
[0100] Fig.13 Shown are arrays and exemplary results when using a multi-biomarker sensor according to the present invention to identify different targets, as described in Example 9.
[0101] Example 1 describes a method for making a composition according to an embodiment of the present invention.
[0102] Examples 2-5 describe exemplary compositions and related targets that can be detected using methods or compositions according to the invention.
[0103] Examples 6-9 describe exemplary compositions and methods for detecting viruses and exemplary compositions, methods, and devices for detecting multiple targets.
[0104] Example 1
[0105] This example provides a method for covalently linking polyclonal antibodies to gold nanoparticles. The method demonstrates the benefits of providing a step of all or part of a polyethylene glycol (PEG) coating on the nanoparticles before the polyclonal antibodies are linked to the nanospheres. The general method used is as follows:
[0106] • Prepare sodium borate buffer 1 M (SBB) pH 8.5.
[0107] • Add 5 microliters of AuNPs to the tube (optionally add polyethylene glycol (PEG) to coat the nanoparticles before attaching to the antibody).
[0108] Add 10 μl NHS (N-hydroxysulfosuccinimide) 0.2M.
[0109] Add 5 μl of EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride) 0.2 M. This step and the previous step constitute the NHS-EDC coupling reaction.
[0110] • Add 1 μl of fluorescent polyclonal antibody (2 mg / ml).
[0111] Add 494 μl of 0.1 M SSB solution and leave overnight at room temperature (20-25°C) to allow the ligation reaction to occur.
[0112] • Centrifuge at 10,000 rpm for 10 minutes to separate the "nanoparticle and polyclonal antibody" complex from the liquid.
[0113] The AuNPs were then washed twice with 0.1 M (SBB) and resuspended in 50 μl of sodium borate buffer 1 M (SBB, pH 8.5).
[0114] Figure 3 and Figure 5 The method is schematically shown at the top. The linking reaction is called the EDC-NHS reaction. It provides a covalent bond between the polyclonal antibody and the gold nanoparticle surface.
[0115] Spherical AuNPs with 10 nm and 40 nm diameters (see Figure 5 A-5D) and goat anti-mouse IgG H&L (a fluorescently labeled antibody) covalently linked. EDC-NHS reaction was used to link the antibody to gold nanoparticles. The formed complex was analyzed by ZOE cell imaging fluorescence microscopy. The parameters used were as follows: Red channel excitation: 556 / 20nm emission: 615 / 61nm.
[0116] Figure 5 A-5D shows the results. Figure 5 A shows 10 nm AuNP + antibody binding without PEG. Figure 5 B shows 40 nm AuNPs + antibody binding without PEG. Figure 5 C shows 10 nm AuNP + antibody binding with PEG. FIG shows 40 nm AuNP + antibody binding with PEG.
[0117] Figure 5 F shows 40 nm AuNPs and goat anti-mouse IgG H&L Fluorescently labeled antibodies were covalently linked. Analysis was performed using a ZOE cell imaging fluorescence microscope. The parameters used were as follows: Green channel excitation: 488 nm emission: 515 / 45 nm.
[0118] The fluorescent markers here show that PEG-treated gold nanoparticles ( Figure 5 C and 5D - high fluorescence) and nanoparticles that have not been treated with PEG ( Figure 5 Difference in polyclonal antibody uptake efficiency between 5a and 5b - low fluorescence).
[0119] Example 2
[0120] In the present embodiment, the target is a protein / enzyme biomarker. In order to test the reaction efficiency of the present invention and the specificity of the protein / enzyme detection, people's anti-topoisomerase II antibody and human DNA topoisomerase 2-alpha protein were used. When reduced to the required final volume, the present invention was proved to be accurate and sensitive. The present invention has specificity to the selected antigen.
[0121] The results are as follows Figure 6 As shown, among them;
[0122] A) Schematic diagram showing protein detection.
[0123] B) shows the results of the reaction in an Eppendorf tube with a final volume of 100 μl:
[0124] Sample tube 1 is a positive control. This tube shows a blue color, which is induced by creating a pH shift (to a high pH value) or by adding a large amount of salt (from a starting red liquid).
[0125] Sample tube 2 is a 10 nm diameter AuNP linked to a monoclonal antibody after adding DNA topoisomerase 2-α protein. The color is red.
[0126] Sample tube 3 is a 40 nm diameter AuNP connected with monoclonal antibody after adding DNA topoisomerase 2-α protein. The color is red.
[0127] Sample tube 4 is a 10 nm diameter AuNP linked to polyclonal human anti-topoisomerase II antibody after adding DNA topoisomerase 2-α protein. The color is blue.
[0128] Sample tube 5 is a 40 nm diameter AuNP linked to polyclonal human anti-topoisomerase II antibody after adding DNA topoisomerase 2-α protein. The color is blue.
[0129] Sample tube 6 is a negative control with only AuNPs linked to polyclonal human anti-topoisomerase II antibodies. The color is red.
[0130] Reactions were performed in serum as reaction buffer. In all cases, a 1 nM (nanomolar) protein / biomarker concentration (DNA topoisomerase 2-alpha protein) was used.
[0131] The monoclonal antibody sample tube did not show a color change from red to blue. The polyclonal antibody sample did show a color change from a red starting solution to a blue solution when DNA topoisomerase 2-alpha protein was added.
[0132] C) shows the change of plasmon color as the biomarker concentration decreases using AuNPs of 40 nanometer diameter and the above-mentioned polyclonal antibodies. These reduced concentrations are represented by the concentrations shown below the tapered wedge and the figure. A final reaction volume of 3 microliters is used. The top row of the figure is a negative control, with only AuNPs connected to polyclonal human anti-topoisomerase II antibodies. The color is red in all cases. The second row shows different concentrations of DNA topoisomerase 2-alpha protein, which are added to the liquid containing AuNPs connected to polyclonal human anti-topoisomerase II antibodies. In the bottom row, all concentrations are shown in blue except that the 1aM (attomole) concentration on the far right of the array remains red.
[0133] Therefore, even at target concentrations as low as 10 x 10 -18 , i.e. 10 attomole (10 aM), the polyclonal antibody-nanoparticle complex also provided a detectable color change.
[0134] D) shows the reaction efficiency (%) as a function of biomarker concentration. A positive 100% individual result means that the color change is obvious and occurs within 5 minutes. Individual results that do not reach these characteristics (e.g., the color change is unclear or takes more than 5 minutes) are designated as 0% reaction efficiency. These bar graphs show the average efficiency taken for 25 individual tests performed for each set of conditions. The results show that even if the biomarker concentration is as low as 10aM, good reaction efficiency can be shown.
[0135] Example 3
[0136] The target in this example is a peptide biomarker. The structure of the peptide and the results of this example are shown in Figure 7 Peptides are short chains of amino acids. Peptides are generally considered to be short chains of two or more amino acids. Peptides are difficult to detect due to their small size. To test the reaction efficiency and specificity of peptide detection, Expression system. We used a polyclonal antibody [anti-DDDDK tag (with Tag sequence binding (ab1162), which is peptide (ddddk peptide) biomarker-specific interaction] covalently linked to 10- and 40-nm diameter gold nanoparticles.
[0137] The results are as follows Figure 7 As shown in A-7C.
[0138] Figure 7 A shows a schematic diagram of peptide detection and the associated color change from red to blue.
[0139] Figure 7B shows the color change indicating the detection. On the right is a photo showing the color change of 3 samples. On the left is a schematic diagram of the color change shown in the photo.
[0140] Sample C in the photo and the corresponding array in the schematic is a control sample to which no peptide was added. The liquid appears red.
[0141] Sample 1 (and the corresponding array in the schematic) shows the 10 nm diameter AuNP + anti-DDDDK polyclonal antibody reaction in the presence of 5 pM peptide. The liquid was light purple.
[0142] Sample 2 (and the corresponding array in the schematic) shows the 40 nm diameter AuNP + anti-DDDDK polyclonal antibody reaction in the presence of 5 pM peptide. The liquid was dark blue.
[0143] Figure 7 C shows the reaction efficiency (%) as a function of biomarker concentration. The reaction efficiency is calculated as follows: when the color change is obvious and occurs within 5 minutes, the reaction efficiency of the individual result is designated as 100%. Individual results that do not reach these characteristics (i.e., the color change is unclear or takes more than 5 minutes) are designated as 0% reaction efficiency. The bar graph on the chart shows the average reaction efficiency taken for 25 individual tests carried out for each group of conditions. The results show that even at concentrations as low as 50aM (attomole), peptide detection has excellent efficiency.
[0144] Example 4
[0145] It has been shown that parasitic / viral / bacterial infections in animals produce elevated levels of stress hormones. To study this type of biomarker, a sensor was prepared to detect the presence of the stress hormone corticosterone (CORT) isolated from avian samples. Commercial avian anti-CORT antibodies were covalently linked to 10 and 40nm AuNPs. Stress hormones in feather samples were obtained by methanol extraction and quantified using a NanoDrop spectrophotometer (A280). A small amount of CORT obtained was added to a liquid according to the present invention. The results show that the color changes even with very small amounts of sample, demonstrating the efficiency of the present invention. Efficiency was also shown in methanol samples, where non-specific (i.e., off-target) aggregation of "nanoparticles + polyclonal antibody complexes" was not detected. In order to demonstrate its specificity, human commercial corticosterone (CORT) was also tested. If the test is specific, no color change is expected when avian anti-CORT antibodies are used for human CORT samples. No color change was detected for human CORT. This shows the specificity of the present invention (i.e., no cross-reaction with human-type biomarkers (hormones in this case)).
[0146] The results are as follows Figure 8As shown in A-8D, wherein;
[0147] Figure 8 A shows a schematic diagram of the hormone detection reaction and the associated color change from red to blue.
[0148] Figure 8 B shows the results of the test using CORT hormone and "anti-avian CORT antibodies". For clarity, the schematic version of each array summarizes the color changes shown in the photographic version. The CORT hormone was extracted from 3 parts of feathers (samples A, B and C) using methanol within 20 minutes. The obtained CORT concentrations were measured by a NanoDrop spectrophotometer (A280). Array (i) shows the liquids according to the present invention before any CORT was added. All liquids are red. Array (ii) shows the liquids after reaction with avian CORT and human CORT.
[0149] Row A (negative control), row B (addition of human CORT) and row C (ultra-low concentration of avian CORT) show no color change. Except for column 8 showing the negative control column, rows DF corresponding to different concentrations of avian CORT all show a color change from red to blue.
[0150] Figure 8 C shows an array for displaying the reaction of gold nanoparticles connected with anti-avian CORT antibodies to human CORT. The i) row shows the control including gold nanoparticles and antibodies in serum. The ii) row shows the control including gold nanoparticles and antibodies in methanol. The iii) row shows the gold nanoparticles and antibodies mixed with human cortisone. In the array, the 1-4 columns relate to nanoparticles with a diameter of 10nm. The 5-8 columns relate to nanoparticles with a diameter of 40nm. The wedge labeled as C shows the qualitative concentration of human cortisone in the iii) row. The concentration range is 0.025ng / microliter to 0.005ng / microliter. As expected, both i) and ii) rows are red. The iii) row shows that in the two cases of nanoparticles of 10 nanometers and 40 nanometer diameters, the human cortisone of different concentrations does not show color change (liquid keeps red). These results show that no matter how the concentration is, any color change is only related to the detection of avian cortisone specificity, and has nothing to do with human cortisone.
[0151] Figure 8D shows the function of reaction efficiency (%) as biomarker concentration.Reaction efficiency is calculated as follows: when color change is obvious and occurs within 5 minutes, the reaction efficiency of individual results is designated as 100%. Individual results that do not reach these characteristics (i.e. color change is unclear or takes time to exceed 5 minutes) are designated as 0% reaction efficiency. The bar graph on the chart shows the average reaction efficiency taken for 25 individual tests carried out for each group of conditions. The result shows that even if concentration is as low as 50aM (attomole), avian cortisone (90% reaction efficiency) can be excellently detected. They have also demonstrated the specificity of detecting avian cortisone relative to human cortisone. For each cortisone concentration, human cortisone "bar" is shown as 0% or 1%.
[0152] Example 5
[0153] In this example, the target is an antibody biomarker. In the first part of this example, anti-IgG, anti-IgM or anti-IgA polyclonal antibodies were attached to AuNPs and used to detect the presence of IgG, IgM or IgA antibody biomarkers. Fig. 9A and 9B shown.
[0154] Fig. 9A : Anti-rabbit IgG polyclonal antibody is covalently linked to AuNP of 40 nanometer diameter. 2.5Au / ml (activity units per ml) and 10AU / ml rabbit IgG samples are used as biomarkers for detection in reaction buffer. 10AU / ml rabbit IgG samples in saliva were also tested. In all samples, the presence of biomarker IgG induces a color change from red to blue. The red top row is a negative control. The results in the array are shown in rows 1-4 for repeated samples.
[0155] Fig. 9B : This figure shows the reaction efficiency (%) as a function of biomarker concentration. The reaction efficiency is calculated as follows: When the color change is obvious and occurs within 5 minutes, the reaction efficiency of the individual result is assigned to 100%. Individual results that do not meet these characteristics (i.e., the color change is not clear or takes more than 5 minutes) are assigned to 0% reaction efficiency. The bar chart on the chart shows the average reaction efficiency taken for 25 individual tests performed for each set of conditions. The results show that even at concentrations as low as 50aM (attomole), excellent reaction efficiency is achieved.
[0156] In the second part of this embodiment, Fig. 9C and 9D The detection of specific type IgG or IgM or IgA antibodies is shown. The antibody to be detected is IgG anti-human DNA topoisomerase II.
[0157] Fig. 9C: Specific antibody detection. DNA topoisomerase II is covalently linked to 40 nm diameter AuNPs. This liquid is red. Human DNA topoisomerase IIα can be viewed as a probe linked to gold nanoparticles to provide starting material.
[0158] In step A, anti-human topoisomerase II IgG polyclonal antibodies from rabbits are added to the starting material (nanoparticles + probes) as biomarkers. The liquid remains red. The added antibodies specifically bind to the DNA topoisomerase II bound to the nanoparticle surface without causing the aggregation of nanoparticles. Now the AuNPs attached with anti-IgG polyclonal antibodies will recognize the presence of IgG anti-human topoisomerase II α.
[0159] In step B, anti-rabbit IgG polyclonal antibody is added to the reaction as a color change inducer. The array shows the red top row (negative control). The 1-4th row shows a replicate. The first, second and third rows are all red. The color change from red to blue is induced only in the bottom row due to the presence of specific anti-human DNA topoisomerase II IgG. Color change will only occur when there is this specific IgG. In the present embodiment, the specific antibodies in the 1.5-10AU / ml scope in the serum can be detected.
[0160] Fig.9D Reaction efficiency (%) is shown as a function of biomarker concentration. Reaction efficiency is calculated as follows: when the color change is obvious and occurs within 5 minutes, the reaction efficiency of the individual result is designated as 100%. Individual results that do not reach these characteristics (i.e., the color change is unclear or takes more than 5 minutes) are designated as 0% reaction efficiency. The bar graph on the chart shows the average reaction efficiency taken for 25 individual tests performed for each set of conditions. The results show that excellent reaction efficiency can be achieved even at concentrations as low as 50aM (attomole) or 1fM (femtomole).
[0161] Fig. 9C and 9D The results presented in show that the two-step technique can be used to detect specific antibodies that themselves bind to specific targets associated with a particular disease.
[0162] In short, biomarkers associated with diseases can be bound to the surface of nanoparticles. A test sample that is believed to contain the corresponding specific antibody can be added to the liquid. Whether the sample contains the target antibody or not, the liquid remains red. The presence of the specific antibody (if present) can then be detected by adding a polyclonal antibody (connected to gold nanoparticles) that is only bound to the specific antibody to be detected. If there is a specific antibody, a color change from red to blue can be induced.
[0163] Example 6
[0164] This embodiment provides a viral antigen sensor, such as Fig.10 Shown schematically.
[0165] As an example of virus detection, the EDC-NHS reaction (see Example 1) can be used to covalently link anti-SARS-CoV-2 (COVID-19) spike (S2) antibodies generated against the recombinant SARS-CoV-2 (2019-nCoV) spike protein (S2) domain or anti-SARS-CoV-2 (COVID-19) nucleocapsid protein (N) antibodies generated against the recombinant SARS-CoV-2 (2019-nCoV) nucleocapsid protein (N) to gold nanoparticles.
[0166] In vitro systems can use SARSCoV-2 spike glycoprotein (S2) and nucleocapsid (N) proteins, both of which are commercial recombinant antigens. The complexed form can be characterized by scanning electron microscopy-energy dispersive X-ray spectroscopy (SEM-EDX) before its use.
[0167] The detector may alternatively be designed to detect the presence of other viruses such as influenza A, influenza B, or HIV-1 CA protein, HIV-1 envelope glycoprotein GP120 HIV-1 GP120, GP 41.
[0168] Antigen detection or capsid protein detection methods can be used to detect the presence of other viruses such as respiratory viruses (RVS). IgG human anti-SARS-CoV-2 can be linked to gold nanoparticles.
[0169] Example 7
[0170] This embodiment provides a viral serological IgG / IgM detector. Fig.11 Such a detector is shown schematically.
[0171] Two sets of nanoparticles were prepared by the EDC-NHS ligation reaction described herein. First, one set of nanoparticles was linked to the COVID antigen as described in Example 6. The Covid antigen formed a probe. Second, one set of nanoparticles was linked to anti-human IgG or human IgM polyclonal antibodies. Both anti-human antibodies are commercially available and do not require any laboratory preparation. The purpose of the sensor is to detect specific human IgG or IgM in the sample, which is produced as a result of the immune response to the COVID-19 virus.
[0172] When a sample containing IgG or IgM antibodies is added to the test liquid (including the probe / antigen-linked nanoparticles and the "anti-human IgG / IgM polyclonal antibody + nanoparticles" complex), the color changes from red to blue. This is because the IgG / IgM in the sample binds to the probe / antigen-linked nanoparticles, and the binding complex then connects to the polyclonal antibody / nanoparticle complex to produce self-assembly.
[0173] This implementation example Fig.11 Schematically shown, which shows the IgG human anti-SARS-CoV-2N protein detection system.
[0174] Example 8
[0175] This embodiment provides a multi-biomarker detector (antigen / IgG / IgM / ) in a single chip.
[0176] The design is as Fig.12 By providing a chip including the composition for detecting IgM and IgG antibodies according to the present invention, the stage of the disease can be informed to the user. Fig.12 The graph in shows the abundance of various antibodies in the virus (new coronavirus infection) over time. The earliest curve shows the increase and subsequent decrease in SARS-CoV-2 RNA and antigen presentation in the body. The second earliest curve shows the production of IgM antibodies early in the infection. As this curve decreases, the third curve shows that the production of IgG antibodies replaces IgM antibodies. Therefore, the presence of IgG antibodies detected by the test can indicate that the infection is in a late stage, while the detection of only IgM antibodies indicates that the patient is still in the early stages of infection. This information can be combined with the test for the presence of specific disease antigens provided in row 4 of the array / device. This information is provided in a single test.
[0177] The array shown has a negative control top row that remains red. Rows 1-4 on the left are samples of clear color only. Rows 4-8 on the right show the blue color induced when a red composition or liquid according to the invention is added to a sample containing the biomarkers shown on the right side of the array.
[0178] Example 9
[0179] This embodiment describes a multi-pathogen detector in a single device. The device can be a chip, such as Fig.13 shown.
[0180] Due to the ability to adapt the present invention to different biomarkers, the methods and devices according to the present invention can detect more than one type of biomarker from a single sample (eg, a single blood, urine, saliva sample).
[0181] The method and device are also capable of testing 10 or more samples. Infectious agents suitable for the method include Helicobacter pylori, poxvirus, tuberculosis (TB), pneumonia and Vibrio cholerae. Using this multi-array detector, one or more selected biomarkers for each infectious pathogen can be tested. By selecting appropriate polyclonal antibodies to combine with biomarkers or multiple biomarkers associated with these diseases, the same sensor can be applied to non-infectious diseases such as cancer and dementia. These embodiments of the present invention are useful because more than one biomarker is usually required to perform correct diagnosis verification of cancer and dementia.
[0182] Fig.13 A schematic diagram of multi-biomarker nanosensor detection in one chip is shown. This embodiment can detect one or more biomarkers to detect different infectious diseases from different samples at the same time. This multi-biomarker nanosensor can be used as a first-round broad-spectrum diagnostic tool for infectious agent identification.
[0183] The array on the left shows the samples before adding the liquid or composition according to the invention (all transparent in color). The middle array shows the samples obtained immediately after adding the composition or liquid according to the invention (all red). The array on the right shows the color change, where the composition / liquid according to the invention has reacted with the sample to provide blue or purple wells in the array. The negative controls in the bottom row remain red.
Claims
1. A composition comprising gold nanoparticles and polyclonal antibodies, wherein: The polyclonal antibody is linked to the gold nanoparticles.
2. The composition according to claim 1, wherein The polyclonal antibodies are each linked to the gold nanoparticles via a covalent bond.
3. A composition according to any one of the preceding claims, wherein The polyclonal antibodies are each linked to the gold nanoparticles via a linker.
4. The composition according to claim 3, wherein The linker includes an N-hydroxysulfosuccinimide derivative group.
5. The composition according to any one of claims 3 or 4, wherein The linker comprises an ester bond.
6. The composition according to any one of claims 3 to 5, wherein The polyclonal antibodies were each attached to the gold nanoparticles via a primary amide group.
7. A composition according to any one of the preceding claims, wherein The polyclonal antibody is suitable for specific binding to one of the following: peptides, proteins, hormones and antibodies.
8. A composition according to any one of the preceding claims, wherein The polyclonal antibodies are suitable for binding to one or more of the following: amyloid beta peptide, CSF biomarkers, natriuretic peptides, IgG, IgM, IgA, CigG, ANA, anti-dsDNA, VOC, CEA, troponin T / C / I, CRP / CD27 / CD38, CA / GP120 / GP41, Cortisol, epinephrine and norepinephrine.
9. A composition according to any one of the preceding claims, wherein The gold nanoparticles are provided with a surface layer of polyethylene glycol.
10. The composition according to claim 9, wherein The polyethylene glycol chain length is 1000-3000, and preferably 1000-2500.
11. A composition according to any one of the preceding claims, wherein The gold nanoparticles are substantially spherical.
12. A composition according to any one of the preceding claims, wherein The diameter of the gold nanoparticles is greater than 3.5 nm.
13. A composition according to any one of the preceding claims, wherein The diameter of the gold nanoparticles is 5-50 nm.
14. A composition according to any one of the preceding claims, wherein The composition is a powder.
15. A composition according to any one of the preceding claims, wherein The composition is lyophilized.
16. A liquid comprising the composition according to any one of claims 1 to 15, wherein The composition including the gold nanoparticles and polyclonal antibodies is dispersed in the liquid.
17. The liquid according to claim 16, wherein The concentration of the composition including the gold nanoparticles and the polyclonal antibody is such that the absorbance of the liquid is 0.1-1 AU.
18. The liquid according to any one of claims 16 or 17, wherein The liquid includes a liquid selected from the following group: water, methanol, plasma, saliva, serum, sodium chloride solution with a concentration of 50mM to 200mM, potassium chloride solution with a concentration of 50mM to 200mM, magnesium chloride solution with a concentration of 5mM to 100mM, 0.1M SSB, and PBS with a concentration lower than 10%.
19. A method for preparing a composition according to any one of claims 1 to 15, comprising the step of linking gold nanoparticles to polyclonal antibodies.
20. The method of claim 19, comprising the step of attaching a linker to the gold nanoparticles prior to linking the gold nanoparticles to the polyclonal antibodies.
21. The method according to claim 20, wherein: The step of attaching a linker to the gold nanoparticles comprises the steps of reacting the gold nanoparticles with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and subsequently reacting with N-hydroxysulfosuccinimide.
22. The method according to any one of claims 19 to 21, wherein: The step of linking the gold nanoparticles to the polyclonal antibodies includes a step in which polyethylene glycol is added to the gold nanoparticles before linking the gold nanoparticles to the polyclonal antibodies.
23. A method for detecting a target in a sample, the method comprising the step of combining the composition according to any one of claims 1 to 15 or the liquid according to any one of claims 16 to 18 with the sample.
24. The method according to claim 23, wherein: The samples had a volume of 3-5 microliters.
25. The method according to any one of claims 23 or 24, wherein: The liquid or the sample according to any one of claims 16-18 comprises a buffer having a pH in the range of 4-9.
26. The method according to any one of claims 23 to 25, wherein: The concentration of the target in the sample was 5 x 10 -18 molar to 1x 10 -9 Moore.
27. The method according to any one of claims 23 to 26, wherein: The sample is a plasma sample, a saliva sample, a urine sample, a soft tissue sample, a serum sample or an aqueous sample.
28. The method according to any one of claims 23 to 27, wherein: The method comprises a diagnostic step, wherein a color change indicates the presence of a target that is a biomarker for a disease, and thereby diagnoses the disease.
29. The method according to any one of claims 23 to 28, wherein: The combination of the composition or liquid and the sample undergoes a color change from red to blue.
30. The method according to any one of claims 23 to 29, wherein: The target is a biomarker, and wherein, when the composition according to any one of claims 1 to 15 or the liquid according to any one of claims 16 to 18 is combined with the sample, gold nanoparticles each linked to a probe that binds to the biomarker are present.
31. The method according to claim 30, wherein: The target is an antibody that binds to the probe.
32. The method according to any one of claims 30 or 31, wherein: The probe is a protein, enzyme, hormone or peptide.
33. A detection test comprising a first composition according to any one of claims 1-15 or a first liquid according to any one of claims 16-18.
34. The detection test of claim 33, wherein: The detection test is suitable for carrying out the method according to any one of claims 23-32.
35. A detection test according to any one of claims 33 or 34, wherein The detection test is adapted to transmit the detection results to a remote location.
36. A detection test according to any one of claims 33 to 35, wherein The detection test comprises a second composition according to any one of claims 1 to 15 or a second liquid according to any one of claims 16 to 18, Wherein, the first composition according to any one of claims 1-15 or the first liquid according to any one of claims 16-18 and the second composition according to any one of claims 1-15 or the second liquid according to any one of claims 16-18 comprise different polyclonal antibodies, so that the first composition or the first liquid and the second composition or the second liquid are suitable for detecting different targets.
37. The detection test of claim 36, wherein: The different targets are all biomarkers associated with specific diseases.
38. A detection test according to any one of claims 36 or 37, wherein The first composition or first liquid and the second composition or second liquid are spaced apart so that they can react independently with different samples.
39. A detection test according to any one of claims 36 to 38, wherein The first composition or first liquid and the second composition or second liquid are suitable for reacting with a single sample or with different samples simultaneously.
